New Era for Malignant Pleural Mesothelioma

Updates on Therapeutic Options

Anne S. Tsao, MD, MBA; Harvey I. Pass, MD; Andreas Rimner, MD; Aaron S. Mansfield, MD


J Clin Oncol. 2022;40(6):681-692. 

In This Article


In summary, the field of mesothelioma has gained momentum with recent therapeutic advances and innovative devices. For clinical practice, it is now essential to know the histologic subtype of mesothelioma and factor this into the decision-making process for frontline systemic therapy. Several ongoing trials in the frontline unresectable setting may soon provide additional treatment options but a key area of need for research remains in the immunotherapy refractory population. In time, it is possible that predictive biomarkers will refine the optimal systemic treatment sequence and justify novel therapies for the patient. These recent advances in adjunct biomedical devices, immunotherapy combinations, and molecular research have generated excitement and hopeful momentum in the field of mesothelioma.